| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Soleno Therapeutics Inc (NASDAQ: SLNO)
SLNO Technical Analysis
5
| As on 9th Jun 2023 SLNO STOCK Price closed @ 5.76 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.60 & Strong Buy for SHORT-TERM with Stoploss of 0.40 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SLNOSTOCK Price
| Open | 6.04 | Change | Price | % |
| High | 6.04 | 1 Day | -0.24 | -4.00 |
| Low | 5.70 | 1 Week | 0.51 | 9.71 |
| Close | 5.76 | 1 Month | 2.06 | 55.68 |
| Volume | 65565 | 1 Year | 5.21 | 947.27 |
| 52 Week High 5.96 | 52 Week Low 0.14 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SLNO Daily Charts |
SLNO Intraday Charts |
Whats New @ Bazaartrend |
SLNO Free Analysis |
|
|
SLNO Important Levels Intraday
| RESISTANCE | 6.42 |
| RESISTANCE | 6.21 |
| RESISTANCE | 6.08 |
| RESISTANCE | 5.95 |
| SUPPORT | 5.57 |
| SUPPORT | 5.44 |
| SUPPORT | 5.31 |
| SUPPORT | 5.10 |
SLNO Forecast May 2024
| 4th UP Forecast | 6.16 |
| 3rd UP Forecast | 6.03 |
| 2nd UP Forecast | 5.95 |
| 1st UP Forecast | 5.87 |
| 1st DOWN Forecast | 5.65 |
| 2nd DOWN Forecast | 5.57 |
| 3rd DOWN Forecast | 5.49 |
| 4th DOWN Forecast | 5.36 |
SLNO Weekly Forecast
| 4th UP Forecast | 6.03 |
| 3rd UP Forecast | 5.94 |
| 2nd UP Forecast | 5.89 |
| 1st UP Forecast | 5.84 |
| 1st DOWN Forecast | 5.68 |
| 2nd DOWN Forecast | 5.63 |
| 3rd DOWN Forecast | 5.58 |
| 4th DOWN Forecast | 5.49 |
SLNO Forecast2024
| 4th UP Forecast | 17.46 |
| 3rd UP Forecast | 13.71 |
| 2nd UP Forecast | 11.39 |
| 1st UP Forecast | 9.07 |
| 1st DOWN Forecast | 2.45 |
| 2nd DOWN Forecast | 0.13 |
| 3rd DOWN Forecast | -2.19 |
| 4th DOWN Forecast | -5.94 |
Soleno Therapeutics Inc ( NASDAQ USA Symbol : SLNO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SLNO Business Profile
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Address: 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service